Capital Advisors Ltd. LLC Trims Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Capital Advisors Ltd. LLC lowered its holdings in Becton, Dickinson and Company (NYSE:BDX) by 4.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,333 shares of the medical instruments supplier’s stock after selling 61 shares during the period. Capital Advisors Ltd. LLC’s holdings in Becton, Dickinson and Company were worth $321,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jennison Associates LLC boosted its holdings in Becton, Dickinson and Company by 4.9% in the first quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock valued at $99,562,000 after purchasing an additional 18,786 shares during the last quarter. Norden Group LLC boosted its holdings in Becton, Dickinson and Company by 2,086.7% in the first quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock valued at $12,853,000 after purchasing an additional 49,559 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Becton, Dickinson and Company by 9.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,422 shares of the medical instruments supplier’s stock valued at $14,481,000 after purchasing an additional 5,006 shares during the last quarter. Axxcess Wealth Management LLC raised its stake in Becton, Dickinson and Company by 30.2% during the first quarter. Axxcess Wealth Management LLC now owns 11,051 shares of the medical instruments supplier’s stock valued at $2,735,000 after buying an additional 2,565 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Becton, Dickinson and Company by 206.5% during the first quarter. SG Americas Securities LLC now owns 46,328 shares of the medical instruments supplier’s stock valued at $11,464,000 after buying an additional 31,215 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.2 %

Shares of Becton, Dickinson and Company stock opened at $238.13 on Monday. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The business’s 50 day simple moving average is $237.46 and its 200-day simple moving average is $235.04. The stock has a market capitalization of $68.82 billion, a price-to-earnings ratio of 52.45, a PEG ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $259.92.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion for the quarter, compared to analysts’ expectations of $5.08 billion. During the same period last year, the firm earned $2.96 EPS. The firm’s revenue was up 2.3% compared to the same quarter last year. Equities research analysts forecast that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Analysts Set New Price Targets

BDX has been the topic of several research reports. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Raymond James cut their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI upped their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, Stifel Nicolaus upped their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.